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Cefodizime, ceftriaxone and cefonicid have similar 
pharmacokinetic profiles, allowing once daily dosing in 
humans [l]. The aim of this study was to evaluate the 
reliability of guinea pigs as an in vivo model of bacterial 
pulmonary clearance, by assessing the antibacterial 
activity of cefodizime, cefonicid and ceftriaxone in vitro 
and in vivo. Thus, after in vih:o testing, we investigated 
the efficacy of eradication of a clinical isolate of Klebsiella 
pnertmoniae causing pulmoinary infection in this 
experimental animal model and the time required for 
this process. I(. pnelrmotiiae was chosen because it may 
be responsible for bacterial pneumonia either in hospital 
or in the community, and there are many reports of its 
use in experimental animal models. 
Fifteen K. pneurnoniae strains, identified by API 
20E (bioMerieux Italia, Rome, Italy), isolated from 
respiratory specimens, were tested for susceptibility to 
the three drugs and the most :sensitive strain (2603) was 
selected. Cefodzime (Hoechst: Marion Roussel, Lainate, 
Italy), cefonicid (SmithKlinl: Beecham Pharmaceu- 
ticals, Bollate, Italy) and ceftriaxone (Roche, Milan, 
Italy), as drug substances of stated potency, were used 
in this study. Killing kinetics were determined for the 
three antibiotics. An inoculum of 106 CFU/mL from 
a mid-logarithmic culture was exposed to different 
antibiotic concentrations (4, 2, 1, 0.5 and 0.25 MIC), 
and incubated at 3 7 T .  At different time points (0, 3, 
6 and 24 h), an aliquot from each tube was suitably 
diluted, spread on Mueller-Hinton agar plates in 
duplicate and incubated at 37’C for 24 h. Results were 
expressed as log CFU/mL of the mean. 
One hundred and fifty female Hartley guinea pigs 
(Charles River, Calco, Italy), weighing from 220 to 250 
g, were used in the experiment. Guinea pigs were 
divided into five groups of 30 animals each. A positive 
control group was infected but received no antibiotic, 
while the negative control group was challenged with 
sterile phosphate-buffered saline (PBS). The remaining 
groups were infected and treated with cefodizime, 
cefonicid and ceftriaxone. The animals were anesthe- 
tized with diethyl ether, the trachea was exposed and 
an inoculum of 100 KL of bacterial suspension (10’ 
celldanimal) or PBS was administered via a sterile 76- 
gauge needle, using an equal volume of air to push the 
bacterial solution directly into the lungs [2,3]. The skin 
incision was closed with surgical staples. The adminis- 
tered antibiotic dose was 15 mg/kg per day. Drug 
substance or sterile saline solution (for the control 
group) was administered intraperitoneally via a sterile 
needle, immediately and after 24 h. At 0, 1, 3, 6, 24 
and 48 h after bacterial challenge, guinea pigs were 
anesthetized with inhaled &ethyl ether and killed by 
cross-clamping. Lungs were harvested in aseptic con- 
ditions and homogenized in saline solution using a 
tissue homogenizer Uanke 81 Kunkel GmbH & Co, 
Staufen, Germany). Homogenates were placed in ice, 
and serial 10-fold dilutions was performed. One 
hundred microliters of each dilution were plated in 
duplicate on Mueller-Hinton agar plates and incubated 
for 18 h at 37OC, after which colonies were counted. 
The mean value obtained from each specimen was 
transformed in logarithms and expressed as CFU/g of 
homogenized lung. 
Sections of lung harvested at the same time points 
chosen for the bacterial count were perfused with 2 mL 
of 4% (vol/vol) paraformaldehyde (Sigma, St Louis, 
MO, USA) in PBS, embedded in paraffin, mounted on 
glass slides, and stained with hematoxylin and eosin. 
Histologic specimens were analyzed by light micro- 
scopy. Results for each group at each time point were 
compared by analysis of variance (ANOVA) and 
considered to be statistically significant when p < 0.05. 
The selected strain showed MIC values [4] of 
0.125 mg/L, 0.062 mg/L and 0.25 mg/L for cefodi- 
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zime, ceftriaxone and cefonicid, respectively. Killing 
curves are shown in Figure 1. The starting inoculum 
(6.0 log CFU/mL) slightly decreased at 3 h both at 0.25 
and at 0.5 MIC for all the tested antibiotics (<1.0 log). 
The decreasing trend continued until the sixth hour for 
cefodizime and ceftriaxone (more than 1.0 log 




4 1  2  
0 4  1 




8 - -  
0 4  
0 3 Time(h) 6 24 
(C )  
log CFUlmL 
I 0  - 
8 - -  
24 Time(h) 0 
+ 4MIC +2MIC +I MIC 
-n- 0.5 MIC +K- 0.25 MIC +Control 
Figure 1 Killing curves against K. pneumoniae (strain 2603) 
of cefodizime (a), ceftriaxone (b) and cefonicid (c). 
3 h, ceftriaxone and cefodizime were bactericidal at 1 
MIC as well as at 2 and 4 MIC (about 2 log decrement). 
At the same time, a concentration of 1 MIC of 
cefonicid exerted a weak bactericidal activity, which 
was more evident at 2 and 4 MIC. After 6 and 24 h 
under the same conditions, the decreasing trend 
continued, but cefodizime and ceftriaxone had lower 
counts than cefonicid. 
Animals infected with K. pnetrmoniae demonstrated 
a progressive development of signs of toxicity, including 
slightly ruffled fur and decreased food intake, and, after 
48 h from inoculation, developed respiratory problems. 
No animal died before being killed at 48 h. No clear 
difference in the signs of infection was seen between 
positive controls and treated animals. At time 0 
(immediately after bacterial challenge), all infected 
animals showed approximately the same mean bacterial 
counts (Figure 2). One hour after challenge, there 
was no change in count and no evidence of any 
difference in lung burden among the groups. Statistical 
analysis demonstrated a significant difference between 
cefodizime- and ceftriaxone-treated groups in com- 
parison with the positive control group at 3, 6, 24 and 
48 h, while the cefonicid group was significantly differ- 
ent from the positive control group after 6, 24 and 48 
h (Figure 2) .  In the control group, decreases of approx- 
imately 0.5 log at 6 h, 1 log at 24 h and 2 logs at 48 h 
were recorded. No significant difference was found 
among treatment groups, although the cefonicid group 
showed slightly greater bacterial survival at 3 and 6 h 
(Figure 2). 
Histologic examination of lungs in the infected 
animals revealed a progressive accumulation of cellular 
infiltrate, predominantly polymorphonuclear leukocytes 
within alveoli, associated with wider alveolar septa, 
perivascular edema, capillary congestion and hemorr- 
hages, reaching a high level after 24 and 48 h from K. 
pneumoniae lung inoculation. The group of animals 
challenged with sterile saline developed a little inflam- 
mation, perhaps due to mechanical injury from the 
deposition of PBS itself, or no inflammation at all. No 
differences in the pathologic pattern between infected 
controls and treated animals were found. 
The experimental animal model was set up 
following the method used by Toews et a1 in mice [3]. 
Our animal model in guinea pigs can be considered to 
be comparable from a histopathologic point of view to 
this murine model of bacterial clearance, and can be 
considered a new experimental model of bacterial 
pulmonary clearance, to stand beside other animal 
models (rat or chinchilla). Some differences in the rate 
of clearance observed in these animal models may be 
mainly due to the bacterial strain utilized. In the present 
model of lung clearance, the lung infection, with local 
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Figure 2 Bacterial clearance of K. pneumoniae by cefodizime, ceftriaxone and cefonicid (strain 1603). Data are expressed as 
mean ? SD. *p<0.05 versus positive control group. 
signs of inflammation, and bacterial growth, were 
confirmed by histologic and microbiological findings. 
The positive control group, infected but not treated, 
was intended to be a good index of host reaction. 
However, in previous descriiptions of experimentally 
induced K.  pneurnoniae infection, such bacterial 
persistence in the lung within 6 h was rarely observed 
[5,6]; this suggests a higher virulence for the strain that 
we used. The histologic pattern observed was similar to 
previous findings in experimentally induced infection 
with the same or other respiratory pathogens [2,6], 
suggesting that different pathogens with different 
pathogenic characteristics :share similar pathologic 
response pathways. As far as. the treated groups were 
concerned, a comparable rate of bacterial clearance 
with ceftriaxone and cefodizime was observed from 3 h 
after bacterial challenge at all the different times of 
observation. Cefonicid showed a less efficient time 
course of bacterial clearance, being significantly 
different from the untreated control only from the sixth 
hour after drug administration. It can be argued that, 
while the in vitro efficacy of these cephalosporins is 
comparable, pharmacokineti c and pharmacodynamic 
parameters, such as the freehound drug ratio and tissue 
penetration index, contribute to the efficacy of the 
antibacterial compounds at the site of infection [7]. For 
this reason, a suitable study to perform a correlation 
between in vivo efficacy and lung or blood drug 
concentrations using this animal model should be 
undertaken. 
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